Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

David Tamborero*#(1), Rodrigo Dienstmann#(2), Maan Haj Rachid(1), Jorrit Boekel(1), Richard Baird(3), Irene Braña(4), Luigi De Petris(5), Jeffrey Yachnin(5), Christophe Massard(6), Frans Opdam(7), Richard Schlenk(8), Claudio Vernieri(9), Elena Garralda(4), Michele Masucci(10), Xenia Villalobos(11), Elena Chavarria(11), Cancer Core Europe consortium, Fabien Calvo(12), Stefan Fröhling(13), Alexander Eggermont(14), Giovanni Apolone(15), Emile E Voest(16), Carlos Caldas(3), Josep Tabernero(17), Ingemar Ernberg(10), Jordi Rodon(18), Janne Lehtiö*(1)

** corresponding authors: david.tamborero@ki.se; Janne.Lehtio@ki.se*
 # both authors contributed equally to this work

Affiliations:
(1) Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden
(2) Medical Oncology - Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
(3) Cancer Research UK Cambridge Centre, Cambridge, UK
(4) Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
(5) Theme Cancer, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
(6) Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
(7) The Netherlands Cancer Institute, Amsterdam, The Netherlands
(8) NCT Trial Center, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany
(9) Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
(10) Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
(11) Research Coordination Area. Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
(12) Gustave Roussy Cancer Campus Grand Paris, Villejuif, France Cancer Core Europe, France
(13) Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany. German Cancer Consortium (DKTK), Heidelberg, Germany
(14) Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands
(15) Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(16) The Netherlands Cancer Institute, Oncode Institute, Amsterdam, the Netherlands
(17) Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, UVic-UCC, Barcelona, Spain
(18) Investigational Cancer Therapeutics Department, University of Texas MD Anderson Cancer Center, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

To the editor: the optimal management of cancer patients is increasingly dependent on individualized treatments guided by tumor sequencing data. As comprehensive genomic tests become routine in many disease settings and academic centers promote *omics*-guided clinical trial recruitment, accurate and scalable data interpretation represents a major challenge. The meticulous task of matching tumor alterations with approved or experimental therapies relies heavily on the expertise of each center. Unsurprisingly, we see similar sequencing results leading to different clinical recommendations[1]. While the number of drug biomarkers with target specificities is constantly growing, these disparities are likely to escalate, which may ultimately impair patients' outcomes and research progress. Access to commercial test results does not simplify decision-making, as they often deliver generic reports that lack the

necessary information to prioritize emerging therapies. In addition, data interpretation must also contend with incidental germline findings, which further complicates the process. Medical teams face the extra burden of manually searching for the latest scientific evidence associated with detected gene alterations, which is a complex, time consuming and error-prone task. Here we argue for the need to streamline expert-driven genomic data interpretation and reporting workflows and employ user-friendly decision support tools that foster interactive treatment planning.

In response, we have developed the Molecular Tumor Board Portal (MTBP), a clinical decision support system that unifies the analysis of sequencing results across seven European comprehensive cancer centers under the umbrella of the Cancer Core Europe (CCE) network[2]. The portal is used to select candidates for the Basket of Baskets trial (NCT03767075), a modular multi-arm study for genomically-defined populations, as well as other clinical studies with active recruitment across CCE sites. Following a process agreed among CCE experts, the system automates *omics* data capture, interpretation and reporting, and creates a framework to share and harness results (Figure). MTBP reports are discussed during weekly virtual meetings where multidisciplinary representatives from each CCE center decide on clinical interventions. These reports are patient-centric web-based documents with the annotations supporting a given variant classification and the complete provenance of all assertions readily accessible through interactive elements. This approach, as opposed to “black box” static documents, empowers intuitive decision-making and case discussion, which may require an in-depth revision of the available information. Variants of clinical interest, such as those qualifying for genetic counseling referral or clinical trial allocation, appear automatically flagged according to CCE predefined criteria. Oncologists acknowledge the advantages of reports with modern user interface design, systematically structured and tailored to the needs of ongoing clinical initiatives, in a system that enables sharing the responsibility of treatment allocation with experts in a truly collaborative manner. Of note, we observed a learning curve to use the portal lasting for approximately 25 reviewed patients. After that, the amount of time devoted to discussing each patient’s case (more than 500 at the moment of writing this manuscript) rarely exceeds four minutes, which is key to scale the process.

A precision oncology decision support tool must give access to the latest clinical actionability evidence and computational analytical tools. Data interpretation can benefit from a variety of publicly available genomics resources, but as variant information exchange standards have not yet been adopted by the community[3], the MTBP implements an extensive data format harmonization to ensure their accurate aggregation. We interpret the patient’s germline and tumor variants in terms of both functional and predictive relevance, two distinct and complementary analyses required for the full range of decision-making of a molecular tumor board. First, the variants’ functionality informs the need for genetic counselling referral when deleterious (pathogenic) germline events in actionable disease-causing genes are detected[4–6]. Importantly, this analysis also provides the necessary information for patient matching to clinical trials with “categorical” inclusion criteria – those that rely on estimating the functional effect of

variants observed in drug targets, such as “activating” mutations in a given oncogene or “loss-of-function” alterations of a tumor suppressor. The MTBP classifies a variant as functionally relevant by integrating up-to-date evidence from multiple expert-curated knowledgebases, *bona fide* biological assumptions and bioinformatics predictions. Second, the predictive interpretation matches functionally relevant variants to biomarkers of disease diagnosis, prognosis and drug response reported at present[7–9]. In addition to on-label prescribing, this informs off-label and experimental drug opportunities to be considered according to current knowledge. Decision support tools are especially useful for target-drug prioritization in complex molecular scenarios, such as tumors with co-occurring alterations known to interact and modify the efficacy of a given drug. The portal ranks the variants’ predictive relevance according to the ESMO’s Clinical Actionability of Molecular Targets scale[10], which factors in the scientific evidence supporting the biomarker effect and gene-drug-disease interactions. As a resource to investigators outside of our network, we recently launched an open access version of the MTBP genomics interpretation pipeline (https://mtbp.org), which provides a general framework to classify the functional and predictive relevance of a given list of variants.

We believe that adoption of cancer type-focused treatment guidelines or access to medical records equipped with clinical pathways are insufficient to meet the full potential of *omics*-guided precision oncology. Instead, the use of stand-alone health technology tools that can provide patient-centered predictive analyses moving beyond generic rules-based criteria will be increasingly important. We advocate that decision support systems driven by academic networks such as the MTBP facilitate the cross-institutional development of clinical trials and real-world data repositories, and accelerate the translation of biomarker discoveries to the clinics. In this regard, we are currently working to incorporate data from emerging biomarkers such as proteomics and digital pathology in our portal. In the near future, these systems will become learning platforms where novel data-to-decision models can be properly assessed and improved. For this to happen, healthcare stakeholders must collaborate to create seamlessly integrated “precision oncology information technologies” and invest in the assets necessary to maintain them.

Competing interests:

David Tamborero reports consultant/advisory fees from Roche. Rodrigo Dienstmann reports receiving honoraria for speaker activities from Roche, Ipsen, Amgen, Sanofi, Servier Laboratories, Merck Sharp & Dohme; advisory role from Roche and Boehringer Ingelheim; and research grants from Merck and Pierre Fabre. Richard Baird reports consultant or advisory roles (with funding to institution) for AstraZeneca, Daiichi-Sankyo, Lilly, Molecular Partners, Novartis, Roche, Shionogi; principal/sub-Investigator of clinical trials for Astex, AstraZeneca, Boehringer-Ingelheim, Boston Therapeutics, Genentech/Roche, Johnson&Johnson, Lilly, Molecular Partners, PharmaMar, Roche, Sanofi-Aventis, Shionogi and Taiho; and research grants from AstraZeneca, Boehringer-Ingelheim and Genentech. Irene Braña reports consultant or advisory role for Orion Pharma; speaker activities for BMS; travel grants from AstraZeneca and Merck Serono; principal investigator of clinical trials for AstraZeneca, BMS, Celgene, Gliknik, GSK, Janssen, KURA, MSD, Novartis, Orion Pharma, Pfizer, Shattuck, Northern Biologics, Rakutan Aspirian and Nanobiotics. Christophe Massard reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune,

MSD, Novartis, Pfizer, Roche, Sanofi, Orion; principal/sub-Investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedicine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro and Xencor. Richard Schlenk reports research funding from Pfizer, AstraZeneca, PharmaMar, Roche, Daiichi Sankyo; speakers honoraria from Pfizer, Daiichi Sankyo, Novartis; participation in Ad Boards: Pfizer, Daiichi Sankyo, Novartis. Elena Garralda reports consultant honoraria from Roche/Genentech, F.Hoffmann/La Roche, Ellipses Pharma, Neomed Therapeutics Inc, Boehringer Ingelheim - Janssen Global Services, AstraZeneca, SeaGen, TFS - Alkermes; research for Novartis / Roche; principal/sub-Investigator of Clinical Trials for Principia Biopharma Inc., Lilly, S.A, Novartis Farmacéutica, S.A, Genentech Inc, Loxo Oncology Inc, F.Hoffmann La Roche Ltd, Symphogen A/S, Merck, Sharp & Dohme de España, S.A, Incyte Biosciences International, Pharma Mar, S.A.U, Kura Oncology Inc, Macrogenics Inc, Glycotope Gmbh, Pierre Fabre Medicament, Cellestia Biotech, Menarini Ricerche Spa, Blueprint Medicines Corporation, Beigene Usa, Inc, Sierra Oncology, Inc, Genmab B.V; travel grants from Bristol-Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope; speakers bureau for Bristol-Mayers Squibb, Merck Sharp & Dohme, Roche, ThermoFisher. Stefan Fröhling reports a consulting or advisory role, having received honoraria, research funding, and/or travel/accommodation expenses funding from the following for-profit companies: Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca, and Pfizer. Alexander Eggermont has received personal fees from Actelion, Agenus, Amgen, Bayer, BMS, Catalym, CellDex, Gilead, GSK, HalioDX, Incyte, IO Biotech, ISA Pharmaceuticals, MedImmune, MSD, Nektar, Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SkylineDx. He has equity in RiverDx, SkylineDx and Theranovir. Giovanni Apolone reports no conflicts of interests with regards to the topic at hand; as scientific director of the Fondazione IRCCS Istituto Nazionale dei Tumori he is legally responsible for contracts with Pharma and other funding agencies. Emile Voest reports no conflict of interest with regards to the topic at hand; as medical director of the Netherlands Cancer Institute he is legally responsible for all contracts with pharma. Carlos Caldas is a member of the External Science Panel of AstraZeneca, a member of Illumina's Scientific Advisory Board and his laboratory has received research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca, and Servier. Josep Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. Jordi Rodon reports research funding from Bayer & Novartis; clinical research for Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAlta, Pfizer, GenMab, CytomX, KELUN-BIOTECH, Takeda-Millennium, GLAXOSMITHKLINE, IPSEN; scientific advisory board for Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceuticals/Klus Pharma, Spectrum Pharmaceuticals Inc., Pfizer, Roche Pharmaceuticals, Ellipses Pharma; research funding for Bayer & Novartis. Janne Lehtiö reports research funding from AstraZeneca, Novartis and GE healthcare, and is co-founder and shareholder of FenoMark Diagnostics Ab. All other authors have no relationships to disclose.

References:

1. Rieke, D. T. *et al.* Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide. *JCO Precis. Oncol.* 1–14 (2018) doi:10.1200/PO.18.00098.

2. Eggermont, A. M. M. *et al.* Cancer Core Europe: A translational research infrastructure for a

European mission on cancer. *Mol. Oncol.* **13**, 521–527 (2019).

3. Wagner, A. H. *et al.* A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. *Nat. Genet.* **52**, 448–457 (2020).
4. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **17**, 405–424 (2015).
5. Landrum, M. J. *et al.* ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res.* **46**, D1062–D1067 (2018).
6. Cline, M. S. *et al.* BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genet.* **14**, (2018).
7. Griffith, M. *et al.* CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. *Nat. Genet.* **49**, 170–174 (2017).
8. Tamborero, D. *et al.* Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. *Genome Med.* **10**, 25 (2018).
9. Chakravarty, D. *et al.* OncoKB: A Precision Oncology Knowledge Base. *JCO Precis. Oncol.* 1–16 (2017) doi:10.1200/PO.17.00011.
10. Mateo, J. *et al.* A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* **29**, 1895–1902 (2018).

Figure Legend

The Molecular Tumor Board Portal automates a common NGS data capture, interpretation and reporting process across Cancer Core Europe centers, currently formed by the Cancer Research UK Cambridge Centre (Cambridge), German Cancer Research Center & National Center for Tumor Diseases

(Heidelberg), Institut Gustave Roussy (Paris), Karolinska Institutet (Stockholm), National Cancer Institute (Milan), Netherlands Cancer Institute (Amsterdam) and Vall d'Hebron Institute of Oncology (Barcelona).

Cancer Core Europe consortium members and affiliations:

Shubha Anand(19), Analía Azaro(4), Danny Baars(20), Svetlana Bajalica-Lagercrantz(21), Judith Balmaña(4), Jonas Bergh(22), Mariska Bierkens(23), Lennart Blomqvist(24), Gary J. Doherty(25), Arnauld Forest(26), Valentina Fornerone(15), Ionut Gabriel Funingana(27), Paola Gabaldi(15), Johan Hartman(28), Peter Horak(13), Claes Karlsson(29), Mary Kasanicki(30), Simon Kreutzfeldt(13), Rolf Lewensohn(22), Johan Lindberg(31), Carlos Lopez(32), Andreas Lundqvist(28), Patricia Martin-Romano(33), Jose-Ezequiel Martin(19), Gerrit Meijer(23), Susana Muñoz(34), Maud Ngo Camus(33), Claudio Nicotra(33), Paolo Nuciforo(35), Petra Oberrauch(13), Päivi Östling(1), Alejandro Piris-Giménez(11), Elena Provenzano(36), Etienne Rouleau(37), John Rowell(38), Omar Saavedra(4), Ignacio Sánchez Valdivia(11), Giovanni Scoazec(15), Kenneth Seamon(3), Marc Tischkowitz(39), Lizet van der Kolk(14), Ruud van der Noll(7), Daniel Vis(40), Ana Vivancos(41), Christina von Gertten(28), Anders Wennborg(10), Lodewyk Wessels(40), Valtteri Wirta(42), Julia Wolfart(43)

(19) Cancer Molecular Diagnostics Laboratory (CMDL), Department of Oncology, University of Cambridge, Cambridge, UK
(20) Biometrics dept. EDC design, Netherlands Cancer institute, Amsterdam, The Netherlands
(21) Department of Oncology-Pathology, Karolinska Institutet and Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
(22) Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
(23) Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
(24) Department of Imaging and Physiology Karolinska University Hospital, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
(25) Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
(26) Institut Gustave Roussy, Villejuif, France
(27) Department of Oncology, University of Cambridge, CRUK Cambridge Institute, Cambridge, UK
(28) Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
(29) Department of Oncology-Pathology, Karolinska Institutet, and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
(30) National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
(31) Science for Life Laboratory, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
(32) Business Development Area. Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
(33) DITEP - Drug Development Department, Gustave Roussy, Villejuif, France
(34) Clinical Research Support Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
(35) Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
(36) National Institute for Health Research Cambridge Biomedical Research Centre Department of Histopathology, University of Cambridge, Cambridge, UK
(37) Tumor Genetic Lab, Gustave Roussy, INSERM UMR 981, Villejuif, France
(38) Institut Gustave Roussy, Cancer Core Europe, Villejuif, France
(39) Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
(40) Division of Molecular Carcinogenesis, The Netherlands Cancer Institute and Oncode Institute, Amsterdam, The Netherlands
(41) Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
(42) Science for Life Laboratory, Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden
(43) Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany



Molecular Tumor Board Portal

Patient data (screening & follow-up)

clinical, pathological and *omics* profiling

Automated data analysis

- data integrity
- data harmonization
- variant annotation
- variant classification
- report generation

In-house and public resources

- knowledgebases
- bioinformatic tools
- expert consensus criteria
- ongoing clinical trials databases

Data repository

Virtual molecular tumor board

- on-label prescription
- clinical trials allocation
- investigational drug opportunities
- genetic counselling referral

novel biomarkers, drug efficacy endpoints and predictive models

Data science